Associate Professor Avi Schroeder โ€“ Technion Israel Institute of Technology

Avi Schroeder is a tenured Associate Professor of Chemical Engineering at the Technion โ€“ Israel Institute of Technology, where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies (https://www.schroederlab.com/ ). ย 
Dr. Schroeder conducted his Postdoctoral studies at the Massachusetts Institute of Technology, and his PhD jointly at the Hebrew and Ben Gurion Universities. Avi is the recipient of more than 30 national and international awards, including being named a KAVLI Fellow, the Intel Nanotechnology-, TEVA Pharmaceuticals-, and the Wolf Foundation Krill Awards. Avi is the author of more than 60 papers, the inventor of 19 patents, and co-founder of multiple startup companies based on these discoveries. Schroeder is a member of the Israel Young National Academy of Sciences, Israelโ€™s National Council for Civilian Research and Development, and the President of the Israel Institute of Chemical Engineers and the Israel Controlled Release Society.

Professor Liam Grover – Healthcare Technologies Institute, University of Birmingham

Liam Grover is Professor in Biomaterials Science at the University of Birmingham. He is a materials scientist by training and completed his PhD in Birmingham before moving to McGill University (Montreal) to work as a CIHR skeletal health scholar. He returned to Birmingham in 2006 to establish a research group within the School of Chemical Engineering. He is expert in the interactions that occur between materials and biological environments, investigating how materials influence biology and He has developed innovative methods that allow for the structuring of ceramic and polymeric materials to significantly change their mechanical and release properties. He has published widely on the development of new materials to replace the function of tissues (more than 200 papers) and has filed more than twenty patents to protect technologies that range from osteogenic cements through to scar reducing dressings. He has given well over 50 invited talks outside the UK. Since starting his career, he has moved four technologies from concept through to clinical trial.He has raised over ยฃ30m to fund his research on the development and translation of novel medical technologies (EPSRC, MRC, BBSRC, ERDF, EU, NC3Rs, NSFC โ€“ China, NIHR, RCDM, and industry) and is the Founder-Director of the Healthcare Technologies Institute, which works to help move novel technologies through the translational pipeline.